Comment on "Symptom Relief and Practice Setting Variation in Bulkamid Injections for Stress Urinary Incontinence"

Urethral bulking agents such as Bulkamid are increasingly used for the management of stress incontinence, with emerging real world evidence supporting their effectiveness.

To critically appraise the recent study by Sze et al. evaluating the symptom relief and practice variation in Bulkamid injections.

This letter is based on a focused critique and discussion of the published study.

While the study provides valuable real world insights, several methodological limitations warrant consideration, including lack of stratification by baseline disease severity, absence of adjustment for concomitant pharmacologic therapies, reliance on subjective outcome measures without objective validation, and potential selection bias in comparisons of anesthesia settings. Furthermore, omission of patient centered outcomes such as satisfaction and goal attainment limits interpretation of clinical success.

Addressing these limitations through more rigorous study design, incorporation of objective patient centered outcomes, and appropriate adjustment for confounders is essential to better define the true effectiveness and durability of Bulkamid and to support informed clinical decision making in stress and mixed urinary incontinence.